We’re building a future where silk heals
We integrate silk biomaterials, bioreactors and 3D bioprinting to recreate functional human bone marrow enabling ex vivo hematopoiesis — unlocking safer cancer therapies, accelerated drug discovery, and truly personalized treatments.
Our technology
Accurate.
Predictive.
Scalable.
We offer advanced three-dimensional bone marrow models that closely mimic in vitro the intricate bone marrow niches. Our models have been extensively validated and are the result of more than 20 years of deep experience in the field.
Our platform transforms hematological and oncological drug development from the ground up—delivering precise disease modeling and intelligent candidate selection that reduces attrition and accelerates translational success. This accurate, predictive, and scalable approach is already trusted by leading pharmaceutical innovators to advance their research and strengthen their drug pipelines.
Our products
Advanced solutions
for bioengineering and research
Silk-based bioinks and hydrogels for precise 3D bioprinting and tissue engineering. Tunable, reproducible, and fully biocompatible.
SilkInk®
SilkThermo®
Bioinks & Hydrogel
Silk scaffolds and bioreactors designed for 3D cell growth and controlled perfusion. Reliable tools for dynamic culture systems.
SilkFold®
SilkFold® Kit
Scaffold
Comprehensive Experiment-as-a-Service solutions delivering reliable, validated, and fast scientific outcomes. Tailored support for research, testing, and product development.
Service
About Us
Made in Europe
We are developing a functionalized bioink that mimics the softness and biocompatibility of human bone marrow with 3D bio-printing to recreate programmable human bone marrow environments where blood cells are produced.
€8m
European Innovation Council Grants
“Science must be visionary, not reactive. At Silk4B, we combine deep experience with nature-inspired design to build sustainable biomedical solutions. Our 3D bone marrow model replaces outdated systems —transforming how we understand and replicate hematopoiesis in the lab.”
Alessandra Balduini
Chief Executive Officer

